|
JP2009526761A
(ja)
*
|
2006-01-30 |
2009-07-23 |
アレイ バイオファーマ、インコーポレイテッド |
ヘテロ二環式チオフェン化合物および使用の方法
|
|
JO3235B1
(ar)
|
2006-05-26 |
2018-03-08 |
Astex Therapeutics Ltd |
مركبات بيررولوبيريميدين و استعمالاتها
|
|
SI3184527T1
(sl)
*
|
2007-06-22 |
2020-03-31 |
Eli Lilly And Company |
Spojine 2,6-diokso,-2,3-dihidro-1H-purina uporabne za zdravljenje stanj povezanih z aktivnostjo TRPA1 kanala
|
|
GB0722055D0
(en)
*
|
2007-11-09 |
2007-12-19 |
Argenta Discovery Ltd |
Compounds
|
|
EA019509B1
(ru)
*
|
2007-11-16 |
2014-04-30 |
Райджел Фармасьютикалз, Инк. |
Карбоксамидные, сульфонамидные и аминовые соединения от метаболических нарушений
|
|
EP2225231B1
(en)
*
|
2007-12-18 |
2011-08-17 |
Actelion Pharmaceuticals Ltd. |
Aminotriazole derivatives as alx agonists
|
|
BRPI0821209A2
(pt)
|
2007-12-19 |
2019-09-24 |
Amgen Inc |
composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor.
|
|
MX2010008700A
(es)
|
2008-02-22 |
2010-08-30 |
Hoffmann La Roche |
Moduladores de beta-amiloide.
|
|
WO2009119088A1
(ja)
*
|
2008-03-25 |
2009-10-01 |
武田薬品工業株式会社 |
複素環化合物
|
|
US8389533B2
(en)
|
2008-04-07 |
2013-03-05 |
Amgen Inc. |
Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
|
|
WO2009140517A1
(en)
|
2008-05-14 |
2009-11-19 |
Hydra Biosciences, Inc. |
Compounds and compositions for treating chemical warfare agent-induced injuries
|
|
GB0812969D0
(en)
|
2008-07-15 |
2008-08-20 |
Sentinel Oncology Ltd |
Pharmaceutical compounds
|
|
US8685980B2
(en)
|
2008-08-22 |
2014-04-01 |
Novartis Ag |
Pyrrolopyrimidine compounds and their uses
|
|
WO2011036889A1
(ja)
*
|
2009-09-25 |
2011-03-31 |
武田薬品工業株式会社 |
複素環化合物
|
|
WO2011036885A1
(ja)
*
|
2009-09-25 |
2011-03-31 |
武田薬品工業株式会社 |
複素環化合物
|
|
US8486967B2
(en)
*
|
2010-02-17 |
2013-07-16 |
Hoffmann-La Roche Inc. |
Heteroaryl substituted piperidines
|
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
|
WO2011121555A1
(en)
|
2010-03-31 |
2011-10-06 |
Actelion Pharmaceuticals Ltd |
Antibacterial isoquinolin-3-ylurea derivatives
|
|
GB201007286D0
(en)
|
2010-04-30 |
2010-06-16 |
Astex Therapeutics Ltd |
New compounds
|
|
EP2566479B1
(en)
*
|
2010-05-07 |
2014-12-24 |
GlaxoSmithKline LLC |
Azaindazoles
|
|
WO2011146313A1
(en)
|
2010-05-19 |
2011-11-24 |
The University Of North Carolina At Chapel Hill |
Pyrazolopyrimidine compounds for the treatment of cancer
|
|
US9512111B2
(en)
|
2010-11-08 |
2016-12-06 |
Lycera Corporation |
N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease
|
|
GB201020179D0
(en)
|
2010-11-29 |
2011-01-12 |
Astex Therapeutics Ltd |
New compounds
|
|
BR112013013790A2
(pt)
|
2010-12-17 |
2016-09-13 |
Hoffmann La Roche |
compostos heterocíclos nitrogenosos 6,6-fundidos substituídos e usos dos mesmos
|
|
WO2012088266A2
(en)
|
2010-12-22 |
2012-06-28 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
|
|
RU2013143839A
(ru)
|
2011-02-28 |
2015-04-10 |
Эррэй Биофарма Инк. |
Ингибиторы сериновых/треониновых киназ
|
|
EP2766349B1
(de)
|
2011-03-08 |
2016-06-01 |
Sanofi |
Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
WO2012120055A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
WO2012120053A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
US8871758B2
(en)
|
2011-03-08 |
2014-10-28 |
Sanofi |
Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
|
US8828994B2
(en)
|
2011-03-08 |
2014-09-09 |
Sanofi |
Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
|
GB201104267D0
(en)
|
2011-03-14 |
2011-04-27 |
Cancer Rec Tech Ltd |
Pyrrolopyridineamino derivatives
|
|
PH12013501940A1
(en)
|
2011-03-23 |
2015-12-04 |
Amgen Inc |
Fused tricyclic dual inhibitors of cdk 4/6 and flt3
|
|
AR088729A1
(es)
|
2011-03-29 |
2014-07-02 |
Actelion Pharmaceuticals Ltd |
Derivados de 3-ureidoisoquinolin-8-ilo y una composicion farmaceutica
|
|
MX340756B
(es)
|
2011-08-04 |
2016-07-25 |
Array Biopharma Inc |
Compuestos de quinazolina como inhibidores de serina/treonina quinasa.
|
|
CA2846187A1
(en)
|
2011-08-23 |
2013-02-28 |
Endo Pharmaceuticals Inc. |
Pyrimido-pyridazinone compounds and use thereof
|
|
EP2567959B1
(en)
|
2011-09-12 |
2014-04-16 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
US9273056B2
(en)
|
2011-10-03 |
2016-03-01 |
The University Of North Carolina At Chapel Hill |
Pyrrolopyrimidine compounds for the treatment of cancer
|
|
GB201118675D0
(en)
*
|
2011-10-28 |
2011-12-14 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201118654D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201118656D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201118652D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
|
PT2820009T
(pt)
|
2012-03-01 |
2018-04-12 |
Array Biopharma Inc |
Inibidores de serina/treonina quinases
|
|
MX361539B
(es)
|
2012-04-25 |
2018-12-10 |
Takeda Pharmaceuticals Co |
Compuesto heterociclico nitrogenado.
|
|
AU2013259624B2
(en)
|
2012-05-08 |
2017-10-19 |
Lycera Corporation |
Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
|
|
EP2846804B1
(en)
|
2012-05-08 |
2017-11-29 |
Merck Sharp & Dohme Corp. |
TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
|
|
KR20150018789A
(ko)
|
2012-05-22 |
2015-02-24 |
더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 |
암의 치료를 위한 피리미딘 화합물
|
|
GB201209613D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201209609D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
|
SI2861595T1
(sl)
|
2012-06-13 |
2017-04-26 |
Incyte Holdings Corporation |
Substituirane triciklične spojine kot inhibitorji fgfr
|
|
WO2014010732A1
(ja)
|
2012-07-13 |
2014-01-16 |
武田薬品工業株式会社 |
複素環化合物
|
|
KR102127026B1
(ko)
*
|
2012-07-27 |
2020-06-25 |
비오겐 엠에이 아이엔씨. |
Atx 조절제들
|
|
US9725462B2
(en)
|
2012-08-07 |
2017-08-08 |
Merck Patent Gmbh |
Pyridopyrimidine derivatives as protein kinase inhibitors
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
EP2882722B1
(en)
|
2012-08-13 |
2016-07-27 |
Takeda Pharmaceutical Company Limited |
Quinoxaline derivatives as gpr6 modulators
|
|
HK1210174A1
(en)
*
|
2012-08-27 |
2016-04-15 |
Array Biopharma, Inc. |
Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases
|
|
GB201216018D0
(en)
|
2012-09-07 |
2012-10-24 |
Cancer Rec Tech Ltd |
Pharmacologically active compounds
|
|
GB201216017D0
(en)
|
2012-09-07 |
2012-10-24 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
|
EP2897954B1
(en)
|
2012-09-21 |
2016-10-26 |
Bristol-Myers Squibb Company |
Fluoroalkyl-1,4-benzodiazepinone compounds
|
|
US9242941B2
(en)
|
2012-09-21 |
2016-01-26 |
Bristol-Myers Squibb Company |
Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds
|
|
WO2014044846A1
(en)
|
2012-09-24 |
2014-03-27 |
Evotec (Uk) Ltd. |
3-(aryl- or heteroaryl-amino)-7-(3,5-dimethoxyphenyl)isoquinoline derivatives as fgfr inhibitors useful for the treatment of proliferative disorders or dysplasia
|
|
US9562047B2
(en)
|
2012-10-17 |
2017-02-07 |
The University Of North Carolina At Chapel Hill |
Pyrazolopyrimidine compounds for the treatment of cancer
|
|
WO2014060381A1
(de)
*
|
2012-10-18 |
2014-04-24 |
Bayer Cropscience Ag |
Heterocyclische verbindungen als schädlingsbekämpfungsmittel
|
|
WO2014085225A1
(en)
|
2012-11-27 |
2014-06-05 |
The University Of North Carolina At Chapel Hill |
Pyrimidine compounds for the treatment of cancer
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
HK1217092A1
(zh)
|
2013-02-15 |
2016-12-23 |
Kala Pharmaceuticals, Inc. |
治疗性化合物及其用途
|
|
US9688688B2
(en)
|
2013-02-20 |
2017-06-27 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
|
|
US9353123B2
(en)
|
2013-02-20 |
2016-05-31 |
Kala Pharmaceuticals, Inc. |
Therapeutic compounds and uses thereof
|
|
JP6280912B2
(ja)
|
2013-03-14 |
2018-02-14 |
武田薬品工業株式会社 |
複素環化合物
|
|
CN104098563A
(zh)
*
|
2013-04-02 |
2014-10-15 |
山东亨利医药科技有限责任公司 |
Jnk抑制剂化合物
|
|
LT2986610T
(lt)
|
2013-04-19 |
2018-04-10 |
Incyte Holdings Corporation |
Bicikliniai heterociklai, kaip fgfr inhibitoriai
|
|
GB201307577D0
(en)
|
2013-04-26 |
2013-06-12 |
Astex Therapeutics Ltd |
New compounds
|
|
WO2015002231A1
(ja)
|
2013-07-03 |
2015-01-08 |
武田薬品工業株式会社 |
複素環化合物
|
|
WO2015002230A1
(ja)
|
2013-07-03 |
2015-01-08 |
武田薬品工業株式会社 |
アミド化合物
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
EP3026051A4
(en)
|
2013-07-24 |
2017-03-08 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|
|
US9890173B2
(en)
|
2013-11-01 |
2018-02-13 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
|
NZ719185A
(en)
|
2013-11-01 |
2017-11-24 |
Kala Pharmaceuticals Inc |
Crystalline forms of therapeutic compounds and uses thereof
|
|
US9682961B2
(en)
|
2013-12-06 |
2017-06-20 |
Carna Biosciences, Inc. |
Quinazoline derivative
|
|
WO2015095788A1
(en)
|
2013-12-20 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
|
|
US9809561B2
(en)
|
2013-12-20 |
2017-11-07 |
Merck Sharp & Dohme Corp. |
Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
|
|
JO3466B1
(ar)
|
2013-12-20 |
2020-07-05 |
Takeda Pharmaceuticals Co |
مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
|
|
WO2015095792A1
(en)
|
2013-12-20 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Carbamate benzoxaxine propionic acids and acid derivatives for modulation of rorgamma activity and the treatment of disease
|
|
RU2016134751A
(ru)
|
2014-01-29 |
2018-03-02 |
Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
Соединения
|
|
UA118369C2
(uk)
|
2014-01-29 |
2019-01-10 |
Глаксосмітклайн Інтеллектьюел Проперті Девелопмент Лімітед |
Сполуки, що інгібують активність lrrk2 кінази
|
|
EP3105230B1
(en)
|
2014-02-14 |
2021-04-07 |
Takeda Pharmaceutical Company Limited |
Pyridopyrazines modulators of gpr6
|
|
WO2015131035A1
(en)
|
2014-02-27 |
2015-09-03 |
Lycera Corporation |
Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma & related therapeutic methods
|
|
GB201403536D0
(en)
|
2014-02-28 |
2014-04-16 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
|
JO3512B1
(ar)
|
2014-03-26 |
2020-07-05 |
Astex Therapeutics Ltd |
مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
|
|
HUE053653T2
(hu)
|
2014-03-26 |
2021-07-28 |
Astex Therapeutics Ltd |
FGFR inhibitor és IGF1R inhibitor kombinációi
|
|
MX370099B
(es)
|
2014-03-26 |
2019-12-02 |
Astex Therapeutics Ltd |
Combinación que comprende un inhibidor de fgfr y un inhibidor de cmet para el tratamiento del cáncer.
|
|
US20150291609A1
(en)
|
2014-04-11 |
2015-10-15 |
The University Of North Carolina At Chapel Hill |
Mertk-specific pyrimidine compounds
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
EP3140291A4
(en)
|
2014-05-05 |
2018-01-10 |
Lycera Corporation |
Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
|
|
EP3209641A4
(en)
|
2014-05-05 |
2018-06-06 |
Lycera Corporation |
Benzenesulfonamido and related compounds for use as agonists of ror and the treatement of disease
|
|
BR112016026150B1
(pt)
|
2014-05-09 |
2019-11-05 |
Pimera Inc |
compostos carboxílicos e seu uso na preparação de medicamentos ou composições farmacêuticas para tratar câncer
|
|
US9758518B2
(en)
|
2015-03-04 |
2017-09-12 |
Pimera, Inc. |
Compositions, uses and methods for making them
|
|
WO2016015598A1
(en)
|
2014-07-26 |
2016-02-04 |
Sunshine Lake Pharma Co., Ltd. |
2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
BR112017013491A2
(pt)
|
2014-12-24 |
2018-01-09 |
Gilead Sciences, Inc. |
compostos de pirimidina fundida para o tratamento de hiv
|
|
TWI699355B
(zh)
|
2014-12-24 |
2020-07-21 |
美商基利科學股份有限公司 |
喹唑啉化合物
|
|
WO2016105534A1
(en)
|
2014-12-24 |
2016-06-30 |
Gilead Sciences, Inc. |
Isoquinoline compounds for the treatment of hiv
|
|
WO2016126570A1
(en)
*
|
2015-02-06 |
2016-08-11 |
Merck Sharp & Dohme Corp. |
Aminoquinazoline compounds as a2a antagonist
|
|
JOP20200201A1
(ar)
|
2015-02-10 |
2017-06-16 |
Astex Therapeutics Ltd |
تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
|
|
EP3256450B1
(en)
|
2015-02-11 |
2020-12-02 |
Merck Sharp & Dohme Corp. |
Substituted pyrazole compounds as ror-gamma-t inhibitors and uses thereof
|
|
SG10201913036RA
(en)
|
2015-02-20 |
2020-02-27 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2016134294A1
(en)
|
2015-02-20 |
2016-08-25 |
Incyte Corporation |
Bicyclic heterocycles as fgfr4 inhibitors
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
US10478494B2
(en)
|
2015-04-03 |
2019-11-19 |
Astex Therapeutics Ltd |
FGFR/PD-1 combination therapy for the treatment of cancer
|
|
JP2018515491A
(ja)
|
2015-05-05 |
2018-06-14 |
リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ |
ＲＯＲγの作動薬及び疾患の療法として使用するジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物
|
|
KR20180025894A
(ko)
|
2015-06-11 |
2018-03-09 |
라이세라 코퍼레이션 |
Rory의 작용제로서 사용하기 위한 아릴 디히드로-2h-벤조[b][1,4]옥사진 술폰아미드 및 관련 화합물 및 질환의 치료
|
|
JP6898919B2
(ja)
|
2015-09-23 |
2021-07-07 |
ヤンセン ファーマシューティカ エヌ．ベー． |
新規化合物
|
|
WO2017050865A1
(en)
|
2015-09-23 |
2017-03-30 |
Janssen Pharmaceutica Nv |
Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
|
|
RU2018117503A
(ru)
|
2015-10-27 |
2019-11-28 |
Мерк Шарп И Доум Корп. |
ЗАМЕЩЕННЫЕ ИНДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RORγТ И ИХ ПРИМЕНЕНИЕ
|
|
JP2018531957A
(ja)
|
2015-10-27 |
2018-11-01 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
ＲＯＲγＴ阻害薬としての置換二環式ピラゾール化合物及びその使用
|
|
AU2016344118A1
(en)
|
2015-10-27 |
2018-05-10 |
Merck Sharp & Dohme Corp. |
Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
|
|
US9630968B1
(en)
|
2015-12-23 |
2017-04-25 |
Arqule, Inc. |
Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
|
|
US10709708B2
(en)
|
2016-03-17 |
2020-07-14 |
The University Of North Carolina At Chapel Hill |
Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
|
|
GB201604647D0
(en)
|
2016-03-18 |
2016-05-04 |
Mission Therapeutics Ltd |
Novel compounds
|
|
AR108326A1
(es)
|
2016-04-27 |
2018-08-08 |
Samumed Llc |
Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
|
|
AR108325A1
(es)
*
|
2016-04-27 |
2018-08-08 |
Samumed Llc |
Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
|
|
CN115028617A
(zh)
*
|
2016-05-24 |
2022-09-09 |
基因泰克公司 |
Cbp/ep300的杂环抑制剂及其在治疗癌症中的用途
|
|
EP3463355B1
(en)
*
|
2016-05-26 |
2024-08-28 |
Sonic Master Limited |
Modulators of dux4 for regulation of muscle function
|
|
CN109563095B
(zh)
*
|
2016-06-02 |
2021-10-29 |
细胞基因公司 |
动物和人抗疟剂
|
|
WO2018029336A1
(en)
|
2016-08-12 |
2018-02-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway.
|
|
SG11201901197PA
(en)
|
2016-08-24 |
2019-03-28 |
Arqule Inc |
Amino-pyrrolopyrimidinone compounds and methods of use thereof
|
|
CA3036065A1
(en)
|
2016-09-08 |
2018-03-15 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
|
CA3036340A1
(en)
|
2016-09-08 |
2018-03-15 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
|
WO2018048747A1
(en)
|
2016-09-08 |
2018-03-15 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
|
EP3601286A4
(en)
|
2017-03-28 |
2020-09-23 |
Pimera, Inc. |
NEW CRYSTALLINE FORMS OF A POL1 INHIBITOR
|
|
MA48994A
(fr)
|
2017-03-30 |
2020-02-05 |
Hoffmann La Roche |
Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
|
|
CN117503775A
(zh)
|
2017-04-28 |
2024-02-06 |
自由生物有限公司 |
治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
GB201709840D0
(en)
|
2017-06-20 |
2017-08-02 |
Inst Of Cancer Research: Royal Cancer Hospital |
Methods and medical uses
|
|
WO2019079626A1
(en)
*
|
2017-10-19 |
2019-04-25 |
Samumed, Llc |
6- (HETEROARYL 5-CHAIN) ISOQUINOLIN-3-YL CARBOXAMIDES, THEIR PREPARATION AND THEIR USE
|
|
US10413537B2
(en)
|
2017-10-27 |
2019-09-17 |
Samumed, Llc |
6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof
|
|
WO2019084497A1
(en)
|
2017-10-27 |
2019-05-02 |
Samumed, Llc |
6- (HETEROARYL AND ARYL WITH 6 CHAINS) ISOQUINOLIN-3-YL CARBOXAMIDES, THEIR PREPARATION AND THEIR USE
|
|
US10703748B2
(en)
|
2017-10-31 |
2020-07-07 |
Samumed, Llc |
Diazanaphthalen-3-yl carboxamides and preparation and use thereof
|
|
PL3788047T3
(pl)
|
2018-05-04 |
2025-04-14 |
Incyte Corporation |
Stałe postacie inhibitora fgfr i sposoby ich otrzymywania
|
|
KR20210018264A
(ko)
|
2018-05-04 |
2021-02-17 |
인사이트 코포레이션 |
Fgfr 억제제의 염
|
|
EP3826722A1
(en)
*
|
2018-07-24 |
2021-06-02 |
F. Hoffmann-La Roche AG |
Isoquinoline compounds and uses thereof
|
|
TW202024053A
(zh)
*
|
2018-10-02 |
2020-07-01 |
美商建南德克公司 |
異喹啉化合物及其用途
|
|
US11612606B2
(en)
|
2018-10-03 |
2023-03-28 |
Genentech, Inc. |
8-aminoisoquinoline compounds and uses thereof
|
|
MA53921A
(fr)
|
2018-10-17 |
2022-01-26 |
Array Biopharma Inc |
Inhibiteurs de protéine tyrosine phosphatase
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
WO2021004547A1
(en)
*
|
2019-07-11 |
2021-01-14 |
Guangdong Newopp Biopharmaceuticals Co., Ltd. |
Heterocyclic compounds as inhibitors of hpk1
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CR20220169A
(es)
|
2019-10-14 |
2022-10-27 |
Incyte Corp |
Heterociclos bicíclicos como inhibidores de fgfr
|
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
AU2020395185A1
(en)
|
2019-12-04 |
2022-06-02 |
Incyte Corporation |
Derivatives of an FGFR inhibitor
|
|
JP7720840B2
(ja)
|
2019-12-04 |
2025-08-08 |
インサイト・コーポレイション |
Ｆｇｆｒ阻害剤としての三環式複素環
|
|
WO2021146424A1
(en)
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
JP2023510918A
(ja)
|
2020-01-15 |
2023-03-15 |
ブループリント メディシンズ コーポレイション |
Ｍａｐ４ｋ１阻害剤
|
|
US11753413B2
(en)
|
2020-06-19 |
2023-09-12 |
Incyte Corporation |
Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
|
|
US11691971B2
(en)
|
2020-06-19 |
2023-07-04 |
Incyte Corporation |
Naphthyridinone compounds as JAK2 V617F inhibitors
|
|
US11767323B2
(en)
|
2020-07-02 |
2023-09-26 |
Incyte Corporation |
Tricyclic pyridone compounds as JAK2 V617F inhibitors
|
|
SI4175719T1
(sl)
|
2020-07-02 |
2025-07-31 |
Incyte Corporation |
Triciklične sečninske spojine kot zaviralci jak2 v617f
|
|
US11661422B2
(en)
|
2020-08-27 |
2023-05-30 |
Incyte Corporation |
Tricyclic urea compounds as JAK2 V617F inhibitors
|
|
KR20230104781A
(ko)
|
2020-10-05 |
2023-07-10 |
인라이븐 테라퓨틱스, 인크. |
Bcr-abl 티로신 키나아제의 억제를 위한 5- 및 6-아자인돌 화합물
|
|
CN114380752A
(zh)
*
|
2020-10-22 |
2022-04-22 |
南开大学 |
一种制备n-取代-2，4-喹唑啉二酮类化合物的合成方法
|
|
WO2022140231A1
(en)
|
2020-12-21 |
2022-06-30 |
Incyte Corporation |
Deazaguaine compounds as jak2 v617f inhibitors
|
|
US11958861B2
(en)
|
2021-02-25 |
2024-04-16 |
Incyte Corporation |
Spirocyclic lactams as JAK2 V617F inhibitors
|
|
TW202304459A
(zh)
|
2021-04-12 |
2023-02-01 |
美商英塞特公司 |
包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
|
|
EP4352060A1
(en)
|
2021-06-09 |
2024-04-17 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
US11939331B2
(en)
|
2021-06-09 |
2024-03-26 |
Incyte Corporation |
Tricyclic heterocycles as FGFR inhibitors
|
|
CN115583946A
(zh)
*
|
2021-07-06 |
2023-01-10 |
赛诺哈勃药业（成都）有限公司 |
杂环化合物及其作为cdk抑制剂的用途
|
|
US12202844B2
(en)
|
2021-07-14 |
2025-01-21 |
Blueprint Medicines Corporation |
MAP4K1 inhibitors
|
|
TW202334089A
(zh)
|
2021-11-02 |
2023-09-01 |
美商夫雷爾醫療公司 |
Ｐｐａｒｇ反向激動劑及其用途
|
|
WO2023126951A1
(en)
|
2022-01-03 |
2023-07-06 |
Yeda Research And Development Co. Ltd. |
Inhibitors of autophagy-related protein-protein interactions
|
|
US12084430B2
(en)
|
2022-03-17 |
2024-09-10 |
Incyte Corporation |
Tricyclic urea compounds as JAK2 V617F inhibitors
|
|
WO2025010279A2
(en)
*
|
2023-07-03 |
2025-01-09 |
Resero Therapeutics, Llc. |
Polo-like kinase 1 inhibitors
|